X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN LTD AUROBINDO PHARMA/
LUPIN LTD
 
P/E (TTM) x 18.9 28.0 67.4% View Chart
P/BV x 4.7 2.9 162.2% View Chart
Dividend Yield % 0.3 0.6 57.9%  

Financials

 AUROBINDO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
LUPIN LTD
Mar-18
AUROBINDO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs8951,465 61.1%   
Low Rs622727 85.5%   
Sales per share (Unadj.) Rs254.6349.6 72.8%  
Earnings per share (Unadj.) Rs39.35.6 706.7%  
Cash flow per share (Unadj.) Rs46.629.6 157.5%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Dividend yield (eoy) %0.30.5 72.3%  
Book value per share (Unadj.) Rs160.0300.3 53.3%  
Shares outstanding (eoy) m585.88452.08 129.6%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x3.03.1 95.0%   
Avg P/E ratio x19.3197.2 9.8%  
P/CF ratio (eoy) x16.337.1 43.9%  
Price / Book Value ratio x4.73.6 129.9%  
Dividend payout %6.490.0 7.1%   
Avg Mkt Cap Rs m444,390495,502 89.7%   
No. of employees `00014.017.0 82.0%   
Total wages/salary Rs m17,67828,647 61.7%   
Avg. sales/employee Rs Th10,667.89,273.6 115.0%   
Avg. wages/employee Rs Th1,264.31,681.0 75.2%   
Avg. net profit/employee Rs Th1,645.8147.4 1,116.3%   
INCOME DATA
Net Sales Rs m149,157158,042 94.4%  
Other income Rs m1,1591,504 77.1%   
Total revenues Rs m150,316159,545 94.2%   
Gross profit Rs m34,34331,475 109.1%  
Depreciation Rs m4,27610,859 39.4%   
Interest Rs m6672,044 32.6%   
Profit before tax Rs m30,55820,076 152.2%   
Minority Interest Rs m50-71 -70.8%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m7,5972,885 263.3%   
Profit after tax Rs m23,0122,513 915.9%  
Gross profit margin %23.019.9 115.6%  
Effective tax rate %24.914.4 173.0%   
Net profit margin %15.41.6 970.4%  
BALANCE SHEET DATA
Current assets Rs m92,062122,095 75.4%   
Current liabilities Rs m66,22350,956 130.0%   
Net working cap to sales %17.345.0 38.5%  
Current ratio x1.42.4 58.0%  
Inventory Days Days10685 125.3%  
Debtors Days Days68120 56.4%  
Net fixed assets Rs m62,919129,876 48.4%   
Share capital Rs m586904 64.8%   
"Free" reserves Rs m93,133134,866 69.1%   
Net worth Rs m93,719135,771 69.0%   
Long term debt Rs m1,81464,245 2.8%   
Total assets Rs m162,494263,054 61.8%  
Interest coverage x46.810.8 432.4%   
Debt to equity ratio x00.5 4.1%  
Sales to assets ratio x0.90.6 152.8%   
Return on assets %14.61.7 841.4%  
Return on equity %24.61.9 1,326.8%  
Return on capital %32.73.7 880.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83853,141 142.7%   
Fx outflow Rs m30,22419,335 156.3%   
Net fx Rs m45,61333,807 134.9%   
CASH FLOW
From Operations Rs m32,78617,512 187.2%  
From Investments Rs m-17,870-14,073 127.0%  
From Financial Activity Rs m-19,153-14,921 128.4%  
Net Cashflow Rs m-4,239-11,482 36.9%  

Share Holding

Indian Promoters % 54.1 46.6 116.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 31.9 86.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.1 101.0%  
Shareholders   69,601 98,259 70.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  MERCK LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 25, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS